Markus Muschen, MD, PhD
Professor
Laboratory Medicine
School of Medicine

R01CA137060-A1 Müschen (PI) 04/01/2008 - 12/31/2012 NCI/NIH “Pre-B cell receptor signaling in acute lymphoblastic leukemia”. The central goal of this project is to clarify the role of pre-B cell receptor signaling in acute lymphoblastic leukemia.

R01CA139032 Müschen (PI) 04/01/2008 - 12/31/2012 NCI/NIH “AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia”. The central goal is (1) to identify the regulatory mechanisms that lead to aberrant expression of AID and (2) to identify the consequences of aberrant AID-activity in leukemia cells.

1R01CA157644 Müschen (PI) 04/01/2011-03/31/2016 NIH/NCI ‘Infectious origins of childhood leukemia’. The central goal of this proposal is to experimentally test the ‘delayed infections hypothesis’ in the etiology of childhood ALL and to delineate mechanisms of genetic vulnerability of human pre-B cells in the context of infection.

R21CA152497 Müschen (PI) 06/01/2010 - 05/31/2012 NCI/NIH “Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia”. The central goals of this proposal are (1) to clarify the role of BCL6 in leukemia-initiation of Ph+ ALL and (2) To determine the frequency and phenotype of BCL6-dependent leukemia stem cells.

TR2-01816 Müschen (PI) 10/01/2010-09/30/2013 California Institute for Regenerative Medicine (CIRM) Early Translation Award. Development of a BCL6 small molecule inhibitor for targeted eradication of leukemia stem cells. The main goals of this project are (1) computer aided drug-design of BCL6 lateral groove inhibitors, (2) PK/PD assays and SAR studies of identified lead compound series and (3) pre-clinical validation.

AACR 138564 Müschen (PI) 12/01/2009 - 11/30/2012 AACR Stand Up To Cancer Innovation Award Stand Up To Cancer Innovation Award: Role of BCL6 in leukemia stem cell self-renewal. The main goal of this project is to study the role of BCL6 in the maintenance of leukemia-initiating cells in ALL.

LLS 1497-11 Müschen (PI) 10/01/2010-09/30/2015 The Leukemia and Lymphoma Society Scholar Award Leukemia and Lymphoma Society Scholar Award, will cover salary expenses related to NIH grant R01CA137060 ‘Pre-B cell receptor signaling in acute lymphoblastic leukemia’.

LLS 6132-09 Müschen (PI) 10/01/2008-09/30/2012 The Leukemia and Lymphoma Society Translational Research Grant ‘Targeting AID in BCR-ABL1-driven leukemia’. The main goal of this project is to study the role of AID in aberrant somatic hypermutation as a cause of genetic instability.

LLS 6097-10 Müschen (PI) 07/01/2009-06/30/2013 The Leukemia and Lymphoma Society Translational Research Grant ‘BCL6 in oncogene-induced senescence’. The main goal of this project is to study the role of BCL6 in oncogene-induced senescence in MYC-driven B cell lymphoma.

LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015 Leukemia and Lymphoma Society SCOR Project 2: Dual targeting of tyrosine kinase and feedback signaling in leukemia. Goals are identification of novel oncogenic tyrosine kinases and characterization of feedback mechanisms in response to tyrosine kinase inhibition. Brian J Druker, Portland, OR is the PI of the SCOR.

LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015 Leukemia and Lymphoma Society SCOR Core E: (1) Generate and make xenografted samples available to SCOR projects, (2) Generate a centralized multidimensional database which links flow cytometry data, cytogenetics, gene expression, SNP chip analysis and clinical information. Brian J Druker, Portland, OR is the PI of the SCOR.

• The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
  Cancer cell 2016 Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, …
• The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
  Cancer cell 2016 Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, …
• Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.
  Oncotarget 2016 Sun H, Lin DC, Guo X, Kharabi Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP
• PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
  Nature medicine 2016 Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M
• Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
  Blood 2016 Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, …
• BCOR regulates myeloid cell proliferation and differentiation.
  Leukemia 2016 Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP
• Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
  Leukemia 2016 Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer …
• MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
  Cell reports 2015 Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H…
• Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia.
  Leukemia 2015 Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne KJ, Dovat S
• Infection and the Perils of B-cell Activation.
  Cancer discovery 2015 Greaves M, Müschen M
• MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
  Blood 2015 Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP…
• Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
  Blood 2015 Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, Schjerven H, Muschen M, Payne KJ, Dovat S
• Infectious origins of childhood leukemia.
  Oncotarget 2015 Swaminathan S, Müschen M
• Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.
  Cancer cell 2015 Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A…
• HSP90 inhibitors decrease AID levels and activity in mice and in human cells.
  European journal of immunology 2015 Montamat-Sicotte D, Litzler LC, Abreu C, Safavi S, Zahn A, Orthwein A, Müschen M, Oppezzo P, Muñoz DP, Di Noia JM
• Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia.
  Nature immunology 2015 Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M
• Ph+ ALL: drawing strength from a benign past.
  Blood 2015 Müschen M
• YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway.
  Journal of hematology & oncology 2015 Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW
• Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.
  Blood 2015 Müschen M
• Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
  Nature 2015 Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW,…
• Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia.
  Nature communications 2015 Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M
• Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.
  Cancer cell 2015 Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan…
• Human lymphoid translocation fragile zones are hypomethylated and have accessible chromatin.
  Molecular and cellular biology 2015 Lu Z, Lieber MR, Tsai AG, Pardo CE, Müschen M, Kladde MP, Hsieh CL
• Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia.
  Immunological reviews 2015 Buchner M, Swaminathan S, Chen Z, Müschen M
• Follicular lymphoma: too many reminders for a memory B cell.
  The Journal of clinical investigation 2014 Swaminathan S, Müschen M
• Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL.
  Scientific reports 2014 Fontanari Krause LM, Japp AS, Krause A, Mooster J, Chopra M, Müschen M, Bohlander SK
• Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.
  Current opinion in hematology 2014 Buchner M, Müschen M
• Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M
• AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine.
  Oncotarget 2014 Tsai CT, Yang PM, Chern TR, Chuang SH, Lin JH, Klemm L, Müschen M, Chen CC
• RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.
  Nature genetics 2014 Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, Jones DR, Ramakrishna M, …
• Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
  Cancer discovery 2013 Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci …
• BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint.
  Trends in immunology 2013 Swaminathan S, Duy C, Müschen M
• VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia.
  Leukemia 2013 Mangum DS, Downie J, Mason CC, Jahromi MS, Joshi D, Rodic V, Müschen M, Meeker N, Trede N, Frazer JK, Zhou Y, Cheng C, Jeha S, Pui CH, Willman CL, Harvey RC, Hunger SP, Yang JJ, Barnette P, Mullighan …
• BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.
  Nature medicine 2013 Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, …
• Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
  Blood 2013 Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, …
• Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
  Oncogene 2013 Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, Kim YM
• O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia.
  The Journal of experimental medicine 2013 Parameswaran R, Lim M, Arutyunyan A, Abdel-Azim H, Hurtz C, Lau K, Müschen M, Yu RK, von Itzstein M, Heisterkamp N, Groffen J
• Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.
  Blood 2013 Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Shojaee S, Klemm L, Parameswaran R, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, …
• Both CpG methylation and activation-induced deaminase are required for the fragility of the human bcl-2 major breakpoint region: implications for the timing of the breaks in the t(14;18) translocation.
  Molecular and cellular biology 2012 Cui X, Lu Z, Kurosawa A, Klemm L, Bagshaw AT, Tsai AG, Gemmell N, Müschen M, Adachi N, Hsieh CL, Lieber MR
• SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.
  Blood 2012 Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M
• Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.
  Cancer cell 2012 Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW
• Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
  Cancer discovery 2012 Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR,…
• IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia.
  PloS one 2012 Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, Ferrari A, Papayannidis C, Paoloni F, Vitale A, Storlazzi CT, Ottaviani E, Guadagnuolo V, Durante S, Vignetti M, Soverini S, Pane F, …
• Zebrafish screen identifies novel compound with selective toxicity against leukemia.
  Blood 2012 Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, …
• Control of B cell development by the histone H2A deubiquitinase MYSM1.
  Immunity 2011 Jiang XX, Nguyen Q, Chou Y, Wang T, Nandakumar V, Yates P, Jones L, Wang L, Won H, Lee HR, Jung JU, Müschen M, Huang XF, Chen SY
• BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
  The Journal of experimental medicine 2011 Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M
• Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.
  Blood 2011 Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M
• Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.
  Blood 2011 Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM
• American Journal of Blood Research: Editorial Board (2011) e-Century Publishing Corporation.
  American journal of blood research 2011 Kwak LW, Goldenberg DM, Benz EJ, Yi Q, Müschen M, Wang D
• Launching of american journal of blood research.
  American journal of blood research 2011 Kwak LW, Goldenberg DM, Benz EJ, Yi Q, Muschen M, Wang D
• BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.
  Nature 2011 Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H,…
• HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S
• Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.
  Science signaling 2011 Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber TG
• ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1.
  Leukemia 2010 Thai M, Ting PY, McLaughlin J, Cheng D, Müschen M, Witte ON, Colicelli J
• Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia.
  Cancer research 2010 Gruber TA, Chang MS, Sposto R, Müschen M
• Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples.
  Cancer research 2010 Fang C, Wang Y, Vu NT, Lin WY, Hsieh YT, Rubbi L, Phelps ME, Müschen M, Kim YM, Chatziioannou AF, Tseng HR, Graeber TG
• Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models.
  Cancer prevention research (Philadelphia, Pa.) 2010 Yun JP, Behan JW, Heisterkamp N, Butturini A, Klemm L, Ji L, Groffen J, Müschen M, Mittelman SD
• BCL6 is critical for the development of a diverse primary B cell repertoire.
  The Journal of experimental medicine 2010 Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, Jumaa H, Koeffler HP, de Alborán IM, Melnick AM…
• A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias.
  Cancer research 2010 Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N
• Genetic relicts from the origin of ALL.
  Blood 2010 Müschen M
• Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations.
  Journal of cellular biochemistry 2010 Wang XM, Greiner TC, Bibikova M, Pike BL, Siegmund KD, Sinha UK, Müschen M, Jaeger EB, Weisenburger DD, Chan WC, Shibata D, Fan JB, Hacia JG
• Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
  Leukemia 2010 Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N
• Pre-B cell receptor signaling in acute lymphoblastic leukemia.
  Cell cycle (Georgetown, Tex.) 2009 Nahar R, Müschen M
• SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
  Blood 2009 Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Thoenissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, …
• The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.
  Cancer cell 2009 Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M
• Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.
  The Journal of experimental medicine 2009 Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, Groffen J, Martinelli G, Heisterkamp N, Jumaa H,…
• Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.
  Cell 2008 Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR
• Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method.
  Haematologica 2008 Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A, Zuntini R, Ferrari S, Ottaviani E, Arruga F, Paolini S, Papayannidis C, Piccaluga PP, Soverini S, Saglio G, Pane F, Baruzzi A, Vignetti M, Berton…
• Highlight: self-renewal signaling in stem cells.
  Biological chemistry 2008 Müschen M
• The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells.
  Biological chemistry 2008 Melchior K, Weiss J, Zaehres H, Kim YM, Lutzko C, Roosta N, Hescheler J, Müschen M
• Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
  Molecular cancer 2007 Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J, Heisterkamp N
• Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.
  The Journal of experimental medicine 2007 Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M
• Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor.
  Immunity 2007 Meixlsperger S, Köhler F, Wossning T, Reppel M, Müschen M, Jumaa H
• Immunoglobulin class-switch recombination occurs in mantle cell lymphomas.
  The Journal of pathology 2006 Klapper W, Szczepanowski M, Heidorn K, Müschen M, Liedtke S, Sotnikova A, Andersen NS, Greeve J, Parwaresch R
• SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells.
  Oncogene 2006 Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M
• The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.
  Oncogene 2006 Sprangers M, Feldhahn N, Herzog S, Hansmann ML, Reppel M, Hescheler J, Jumaa H, Siebert R, Müschen M
• BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
  Oncogene 2006 Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Müschen M
• Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.
  Proceedings of the National Academy of Sciences of the United States of America 2005 Feldhahn N, Río P, Soh BN, Liedtke S, Sprangers M, Klein F, Wernet P, Jumaa H, Hofmann WK, Hanenberg H, Rowley JD, Müschen M
• B-lymphoid or myeloid lineage identity of cell lines derived from chronic myeloid leukemia blast crisis.
  Cancer genetics and cytogenetics 2005 Soh BN, Klein F, Feldhahn N, Müschen M
• Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.
  The Journal of experimental medicine 2005 Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, Bekhite MM, Hofmann WK, Herzog S, Jumaa H, Rowley JD, Müschen M
• Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Klein F, Feldhahn N, Mooster JL, Sprangers M, Hofmann WK, Wernet P, Wartenberg M, Müschen M
• The molecular requirements for LAT-mediated differentiation and the role of LAT in limiting pre-B cell expansion.
  European journal of immunology 2004 Su YW, Herzog S, Lotz M, Feldhahn N, Müschen M, Jumaa H
• Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells.
  Cell cycle (Georgetown, Tex.) 2004 Klein F, Feldhahn N, Müschen M
• A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential.
  The Journal of experimental medicine 2004 Kögler G, Sensken S, Airey JA, Trapp T, Müschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada…
• The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells.
  The Journal of experimental medicine 2004 Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, Wernet P, Siebert R, Müschen M
• Epstein-Barr virus and the B cell: a secret romance.
  Trends in microbiology 2003 Schuster VH, Müschen M
• T lymphoid differentiation in human bone marrow.
  Proceedings of the National Academy of Sciences of the United States of America 2003 Klein F, Feldhahn N, Lee S, Wang H, Ciuffi F, von Elstermann M, Toribio ML, Sauer H, Wartenberg M, Barath VS, Krönke M, Wernet P, Rowley JD, Müschen M
• Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species.
  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003 Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, Petrat K, Pütz V, Hescheler J, Sauer H
• Molecular portraits of B cell lineage commitment.
  Proceedings of the National Academy of Sciences of the United States of America 2002 Müschen M, Lee S, Zhou G, Feldhahn N, Barath VS, Chen J, Moers C, Krönke M, Rowley JD, Wang SM
• The origin of CD95-gene mutations in B-cell lymphoma.
  Trends in immunology 2002 Müschen M, Rajewsky K, Krönke M, Küppers R
• Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene.
  International journal of cancer 2001 Müschen M, Re D, Betz B, Moers C, Wolf J, Niederacher D, Diehl V, Beckmann MW
• Molecular single-cell analysis of Hodgkin- and Reed-Sternberg cells harboring unmutated immunoglobulin variable region genes.
  Laboratory investigation; a journal of technical methods and pathology 2001 Müschen M, Küppers R, Spieker T, Bräuninger A, Rajewsky K, Hansmann ML
• Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells.
  Cancer research 2001 Re D, Müschen M, Ahmadi T, Wickenhauser C, Staratschek-Jox A, Holtick U, Diehl V, Wolf J
• Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions.
  Blood 2001 Küppers R, Bräuninger A, Müschen M, Distler V, Hansmann ML, Rajewsky K
• Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction.
  The Journal of experimental medicine 2000 Müschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Küppers R
• Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells.
  Cancer research 2000 Müschen M, Re D, Bräuninger A, Wolf J, Hansmann ML, Diehl V, Küppers R, Rajewsky K
• CD95 ligand expression as a criterion of malignant transformation in breast cancer.
  The Journal of pathology 2000 Müschen M, Beckmann MW
• Rare occurrence of classical Hodgkin's disease as a T cell lymphoma.
  The Journal of experimental medicine 2000 Müschen M, Rajewsky K, Bräuninger A, Baur AS, Oudejans JJ, Roers A, Hansmann ML, Küppers R
• CD95 ligand expression as a mechanism of immune escape in breast cancer.
  Immunology 2000 Müschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann MW
• Defining CD95 as a tumor suppressor gene.
  Journal of molecular medicine (Berlin, Germany) 2000 Müschen M, Warskulat U, Beckmann MW
• CD95 ligand expression in dedifferentiated breast cancer.
  The Journal of pathology 1999 Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW, Häussinger D
• Involvement of soluble CD95 in Churg-Strauss syndrome.
  The American journal of pathology 1999 Müschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Häussinger D
• Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation.
  Gastroenterology 1999 Müschen M, Warskulat U, Peters-Regehr T, Bode JG, Kubitz R, Häussinger D
• Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.
  International journal of cancer 1999 Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW, Häussinger D
• A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance.
  The Journal of clinical investigation 1998 Josien R, Douillard P, Guillot C, Müschen M, Anegon I, Chetritt J, Menoret S, Vignes C, Soulillou JP, Cuturi MC
• Deranged CD95 system in a case of Churg-Strauss vasculitis.
  Gastroenterology 1998 Müschen M, Warskulat U, Häussinger D, Moers C, Simon D, Even J
• Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells.
  Hepatology (Baltimore, Md.) 1998 Müschen M, Warskulat U, Douillard P, Gilbert E, Häussinger D